Stock search

Ticker or company name

Compare stocks

Market: US

  • MRNAModerna

Add stock

Ticker or company

Summary

MRNA
Moderna
$215,27Down −3,63%
Year: Up +795%
22/100Ratio would not consider buying
Open stock page

Verdict

MRNA has 7 of 10 checks in the red zone.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckMRNA2 ✓ 0 — 7 ✕
P/E vs its history—
P/E vs industry—
Forward P/En/a—
Revenue growth, YoY+13,1%
EPS growth, YoY—
Net margin−110,5%
Net debt / EBITDA—
Free cash flow−$1,97 bn
Share count over a year+10,3%
Cash runway0,8 yrs

Metrics

Best WorstNo mark — in between

Metric · betterMRNATTMIndustry medianTTM
P/E TTM ↓n/a42,1
Forward P/E ↓n/a18,7
PEG ↓n/a4,1
P/S TTM ↓35,86,6
EV/EBITDA ↓105,928,2
P/FCF ↓101,426,0

Price, %

  • MRNAn/a

Returns

Best WorstNo mark — in between

PeriodMRNA
1 yearn/a
3 yearsn/a
5 yearsn/a
All timen/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

MRNA
Share of “buy”32%
Beat the forecast4 of 4
Average “surprise”+43,7%
Insiders over 12 monthssales $78,9 m

Details are on each stock page.